Comparison of the current study with randomized controlled trials of leukoreduction and alloimmunization
. | . | . | Chemotherapy patients %*(P) . | . | SCT patients %*(P) . | . | Parous/transfused patients %* (P value) . | . | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Study . | Sample size . | Prestorage LR . | Allo . | Ref . | Allo . | Ref . | Allo . | Ref . | |||
| Current study | 716 | Yes | 13 (.01) | 9 (.04) | 13 (.004) | 11 (.003) | 14 (.02) | 12 (.005) | |||
| TRAP7 | 400 | No | 28 (< .0001) | 9 (.03) | — | — | 29 (.02) | — | |||
| Sintnicolaas et al8 | 46 | No | NS | NS | — | — | NS | NS | |||
| Williamson et al6 | 123 | No | 31 (.025) | NS | NS | NS | — | — | |||
| van Marwijk Kooy et al5 | 53 | Yes | 35 (< .04) | 35 (< .05) | — | — | NS | NS | |||
| Oksanen et al4 | 31 | No | NS | NS | — | † | NS | NS | |||
| Andreu et al2 | 69 | No | 20 (< .05) | 26 (< .02) | — | — | — | — | |||
| Sniecinski et al3 | 40 | No | 35 (.01) | 35 (.01) | — | — | NS | — | |||
| Schiffer et al1 | 98 | No | NS | NS | — | — | 37 (.05) | — | |||
. | . | . | Chemotherapy patients %*(P) . | . | SCT patients %*(P) . | . | Parous/transfused patients %* (P value) . | . | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Study . | Sample size . | Prestorage LR . | Allo . | Ref . | Allo . | Ref . | Allo . | Ref . | |||
| Current study | 716 | Yes | 13 (.01) | 9 (.04) | 13 (.004) | 11 (.003) | 14 (.02) | 12 (.005) | |||
| TRAP7 | 400 | No | 28 (< .0001) | 9 (.03) | — | — | 29 (.02) | — | |||
| Sintnicolaas et al8 | 46 | No | NS | NS | — | — | NS | NS | |||
| Williamson et al6 | 123 | No | 31 (.025) | NS | NS | NS | — | — | |||
| van Marwijk Kooy et al5 | 53 | Yes | 35 (< .04) | 35 (< .05) | — | — | NS | NS | |||
| Oksanen et al4 | 31 | No | NS | NS | — | † | NS | NS | |||
| Andreu et al2 | 69 | No | 20 (< .05) | 26 (< .02) | — | — | — | — | |||
| Sniecinski et al3 | 40 | No | 35 (.01) | 35 (.01) | — | — | NS | — | |||
| Schiffer et al1 | 98 | No | NS | NS | — | — | 37 (.05) | — | |||
LR indicates leukoreduction; SCT, stem cell transplantation; —, not done; and NS, not significant.
Absolute percent reduction in incidence of HLA alloimmunization (Allo) or alloimmune refractoriness (Ref). Differences are listed only for statistically significant changes; other results are listed as NS.
Only 3 patients underwent SCT in this study.